GENE ONLINE|News &
Opinion
Blog

2025-12-02|

Iodide Catalyst Enables Efficient Electrochemical Conversion of CO₂ to Multi-Carbon Products in Acidic Conditions

by GOAI
Share To

Researchers have identified a method to enhance the electrochemical reduction of carbon dioxide (CO₂) into multi-carbon (C₂+) products in acidic environments using iodide as a catalyst. This process converts CO₂, a greenhouse gas, into valuable hydrocarbons such as ethylene, which can serve as chemical feedstocks. The approach addresses two critical challenges: reducing atmospheric CO₂ levels and producing useful compounds for industrial applications.

The study highlights the role of iodide in facilitating this transformation under acidic conditions, which are typically less favorable for CO₂ reduction reactions. Acidic environments often pose difficulties for achieving high selectivity and efficiency in producing multi-carbon products. However, researchers demonstrated that iodide enhances the reaction’s performance by stabilizing intermediates involved in the conversion process. The findings suggest that this method could improve the viability of electrochemical CO₂ reduction technologies, offering potential pathways for sustainable chemical production while addressing climate change concerns.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
LATEST
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
2025-12-04
2025 Healthcare+ Expo Taiwan
Taipei, Taiwan
Scroll to Top